Dr. Peter Tessier
Department of Chemical Engineering and Pharmaceutical Sciences
University of Michigan
Title: “Improved methods for designing, evolving and characterizing monoclonal antibodies”
The biotech industry has seen an explosion in the development of therapeutic antibodies in the last decade, and today most of the top selling drugs are monoclonal antibodies. The advantages of antibodies as therapeutics – namely their high affinity, specificity, potency, stability, manufacturability and low toxicity – are compelling. Nevertheless, there are many fundamental challenges associated with antibody discovery and development that require key technical advances to improve the rational and reliable generation of potent antibody therapeutics. I will discuss our progress in addressing some of these fundamental challenges, including the design, evolution, selection and characterization of antibodies with high affinity, specificity, stability and solubility.
Host: Dmitry Kurouski
Location: 108 Biochemistry Building (Bldg#1507)